人外淋巴液、脑脊液和血液中的Prestin作为听力损失生物标志物
研究纳入42例接受经迷路或中颅窝肿瘤切除术的内听道或耳蜗内肿瘤患者,术中采集血液、脑脊液和外淋巴液,用酶联免疫吸附试验测定Prestin浓度。外淋巴液Prestin浓度显著高于血液和脑脊液,脑脊液Prestin浓度与术前听力水平显著相关,血液和外淋巴液则无相关性。
要点
- 外淋巴液Prestin中位浓度84.74 ng/mL,显著高于血液1.32 ng/mL和脑脊液4.73 ng/mL。
- 脑脊液Prestin浓度与术前纯音平均和言语识别率显著相关,血液和外淋巴液无相关性。
- Prestin检测试剂盒尚未获临床批准,转化为诊断工具前需进一步研究。
核心结论
- 本研究发现Prestin水平具有波动性,并首次提供了除血液外其他体液中该潜在生物标志物的浓度信息。
- 未来研究应全面评估不同病因感音神经性听力损失患者的Prestin水平、Prestin的自然稳态与体循环以及耳蜗创伤后的时间动态变化。
- 在考虑该诊断技术潜在转化应用之前,亟需临床批准的Prestin检测试剂盒。
研究设计与样本
- 研究类型为人体样本检测研究,术中采集42例内听道肿瘤或耳蜗内肿瘤患者的血液、脑脊液和外淋巴液样本。
- Prestin浓度采用酶联免疫吸附试验测定,并进行线性回归分析探究其与听力学及前庭检查结果的关联。
- 研究在三级转诊中心开展。
主要发现
- 42例研究参与者(26例女性,平均±标准差年龄52.7±12.5岁)血液样本Prestin中位浓度为1.32 ng/mL(四分位距0.71-1.99)。
- 脑脊液Prestin水平显著更高,为4.73 ng/mL(四分位距2.45-14.03)(P = .005)。
- 外淋巴液Prestin浓度为84.74 ng/mL(四分位距38.95-122.00),显著高于血液(P = .01)和脑脊液(P = .03)水平。
- 线性回归分析显示脑脊液Prestin浓度与术前听力水平(纯音平均和言语识别率)显著相关(P = .008,R2 = 0.1894;P = .03,R2 = 0.1857),但与血液或外淋巴液水平无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出未来研究需全面评估不同病因感音神经性听力损失患者的Prestin水平、Prestin的自然稳态与体循环以及耳蜗创伤后的时间动态变化。
- 原文指出在考虑该诊断技术潜在转化应用之前,亟需临床批准的Prestin检测试剂盒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori-neural hearing loss (SNHL). STUDY DESIGN: Human blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme-linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results. SETTING: Tertiary referral center. RESULTS: The median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71-1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45-14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95-122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure-tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels. CONCLUSION AND RELEVANCE: This study's findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker's concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin's natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique.
引用
- Gadenstaetter AJ, Krumpoeck PE, Auinger AB, et al. Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss. Otolaryngol Head Neck Surg. 2024. PMID: 38988299. doi:10.1002/ohn.895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。